Houston healthtech startup raises $30M to scale surgical healing gel

fresh funding

The company's B3 GEL System is designed to protect tendons, ligaments and muscles while they heal from orthopedic surgery. Photo via Unsplash

Houston-based healthtech startup TYBR Health has raised a $30 million Series A round to scale its B3 GEL System, which helps protect tendons from scarring after surgery.

The round was led by Minneapolis-based Vensana Capital and Cleveland-based Mutual Capital Partners, with participation from Denver-based Neovate Capital Partners and existing investors, according to a news release from the company.

TYBR Health said it plans to use the funding to broaden the B3 GEL System's clinical applications, expand commercialization and conduct studies to evaluate its ability to protect tissue and improve healing outcomes.

"Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed ... There's a shift underway across surgical specialties, from focusing almost entirely on the mechanical repair to also weighing the biological conditions that repair needs to succeed," Tim Keane, co-founder and CEO of TYBR Health, said in the news release. "This financing lets us reach more surgeons and generate the clinical evidence to move that shift forward."

As part of the financing round, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR board, alongside independent director Aaron Smith.

"TYBR Health is addressing a gap surgeons have lived with for a long time, with a product that fits the way they already work," Zambory, principal at Mutual Capital Partners, added in the release. "We're excited to co-lead this round and support the company's growth."

TYBR was founded in 2020 and originated from the TMCi’s Biodesign fellowship and participated in the TMC's Accelerator for HealthTech. Its B3 GEL System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal from orthopedic surgery. It received FDA 510(k) clearance last June and launched an Australian clinical trial in the fall.

The B3 GEL System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures since it launched, according to the company, and was first used in the clinical setting earlier this year by Dr. Tammam Hanna with Texas Tech University Health Sciences Center.

From Your Site Articles
Here are the eight companies currently being accelerated by Texas Medical Center Innovation. Photo courtesy of TMC

TMC names latest cohort of health tech innovators for 2024 program

ready to grow

The Texas Medical Center Innovation has named its new cohort of health tech companies it's currently accelerating.

This first batch of companies for 2024 was selected from last fall's TMC Bootcamp. Eight of the 10 startups from the bootcamp have moved on to the Accelerator for HealthTech.

"Hailing from diverse corners of the globe—from the tech corridors of Texas and California to Ireland and Australia—these companies converge with a shared mission—to move healthcare forward," Devin Dunn, head of the Accelerator for Health Tech, writes in a TMC blog post. "Through personalized mentorship and guidance, these eight companies are able to navigate complex challenges and refine their strategies, while leveraging the expertise of Texas Medical Center ecosystem to validate their innovations and drive real-world impact."

The selected companies include:

  • AcorAI, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
  • Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
  • San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
  • NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
  • Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
  • From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
  • TYBR, also based in Houston, created a flowable extracellular matrix hydrogel, crafted to safeguard healing tendons and ligaments from scarring and adhesions. The company originated from the TMCi’s Biodesign fellowship and now has entered into the Accelerator for HealthTech to sharpen its regulatory strategy, particularly in anticipation of FDA conversations.

Applications for the next Accelerator for HealthTech will open in May of this year.

Eight of the 10 most-promising life science startups named at BioHouston and the Rice Alliance's event are based in Houston. Photo courtesy of Rice Alliance

Houston startups named most promising in the life science space at annual event

ones to watch

For the second time this year, Houston life science leaders and startup founders gathered to discuss the future of health care in Houston.

The annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship was usually held during the fall before the pandemic pushed it off schedule. In February, the two organizations hosted the previous forum, but as of this month, the annual event is back on track.

The day included panels and networking, plus over 50 companies — about half of which are based in Houston — pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Houston-based Bairitone Health won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The company is creating a wearable technology that takes a more innovative approach to sleep apnea and snoring with its SOMNAR platform that detects tissue-born sounds, identifies obstructions, and more. The award was presented by Ann Tanabe, CEO of BioHouston.

Ann Tanabe, CEO of BioHouston, presented the DeBakey Award to Houston-based Bairitone Health. Photo courtesy of Rice Alliance

For the first time, the event also named a people's choice award winner, as voted on by the audience members. Baritone Health also claimed the prize.

At the conclusion of the event, the Rice Alliance and BioHouston named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Autonomize

Austin-based Autonomize unlocks data and context to enable human health outcomes

bEHR Health Systems

New Orleans-based bEHR Health Systems delivers, medical, lifestyle, and social solutions to health for African Americans.

EMPIRI

EMPIRI, based in Houston, is revolutionizing cancer care with a novel technology that accurately predicts each cancer patient's treatment responses empirically, enabling doctors to make the optimal treatment selection for each cancer patient.

InformAI

Houston-based InformAI develops AI-based medical image diagnostic tools and uses large dataset synthesis to develop clinical outcome predictors for physicians, hospitals, and medical imaging/medical device companies

March Biosciences 

Houston-based March Biosciences is impacting the most challenging lymphoma and leukemia.

MRG Health-SmartCare360

MRG Health-SmartCare360, based in Houston, is a determinate of health and disease specific virtual care management technology and services company that improves patient access to care and clinical outcomes for people suffering from one or more chronic disease.

Prana Thoracic

Prana Thoracic, founded in Houston out of JLABS at TMC, is a medical device startup that's innovating for the future of early intervention in lung cancer.

Steradian Technologies

Another med device startup based in Houston, Steradian Technologies employs deep-photonics technology to diagnose respiratory diseases in seconds, all for the price of a latte.

TYBR Health

Houston-based TYBR Health makes a hydrogel that protects tendons from scarring after surgery and improves patient outcomes.

Voythos

Voythos, based in Houston, is making medical records work for today's healthcare.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings